Skip to content

MediciNova rallies on preclinical data for rationale of COVID-19 vaccine

September 11, 2020

MediciNova (NASDAQ:MNOV) is up 13% premarket on light volume in reaction to the announcement of encouraging preclinical results on an intranasal RSV vaccine by SARS-CoV-2 vaccine development partner BioComo.

The RSV vaccine, based on BP-PIV and VLP-BC-PIV platform technology developed by BioComo and Mie University, induced high neutralizing antibody titers in mice.

BC-PIV, a non-transmissible viral vector derived from the recombinant human parainfluenza virus type 2 (hPIV2), is the same vector used in their intranasal COVID-19 vaccine candidate.

The RSV vaccine mouse study was conducted at Fraunhofer Institute (IZI) for Cell Therapy and Immunology in Leipzig, Germany. MNOV plans to work with IZI on animal studies for the COVID-19 vaccine.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: